Stockreport

Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com
PDF – Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 mi [Read more]